Athira Pharma Acquires Lasofoxifene Development Rights, Secures $90 Million Financing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 18 2025
0mins
Should l Buy ?
Source: Globenewswire
- Financing Support: Athira Pharma has completed a $90 million private placement financing co-led by Commodore Capital and others to support the development of Lasofoxifene, which is expected to drive its clinical data release in mid-2027.
- Clinical Trial Progress: The ongoing ELAINE-3 clinical trial is over 50% enrolled, positioning Lasofoxifene to potentially become the new standard of care for ESR1-mutant metastatic breast cancer, addressing a significant market gap.
- Market Potential: The metastatic breast cancer market is projected to reach $41.7 billion by 2030, with Athira's Lasofoxifene poised to capture a significant share by meeting the needs of approximately 40% of patients.
- Strategic Importance: Athira's CEO emphasized that this acquisition marks a crucial step in the company's strategic development, aiming to enhance patient quality of life through innovative therapies while delivering lasting value for shareholders.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
